News | April 29, 2022
Ami Organics earmarks Rs 190 cr to expand API production in Ankleshwar
The plant is expected to start commercial operations from Q4FY24
The plant is expected to start commercial operations from Q4FY24
Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021
Since its inception, the company has either acquired or taken a majority stake in five companies
The drug is being developed at lab scale for the first-line of treatment of Covid-19
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector
Expands manufacturing push & locks in major growth deals
Subscribe To Our Newsletter & Stay Updated
